World Lung Cancer Day – August 1, 2024
“Every year on August 1st, people around the globe come together to observe World Lung Cancer Day. This important health awareness day serves as a reminder of the ongoing battle against one of the most prevalent and deadly forms of cancer. It’s a time to educate, support, and inspire action in the fight against lung cancer, which continues to be a significant global health challenge.”
Chemotherapy plus nintedanib has ‘promising’ efficacy in small cell lung cancer with IPF
“Key takeaways: A pharmacotherapy is needed for patients with small cell lung cancer plus IPF. Patients frequently experienced grade 3 or greater neutropenia, leukopenia and thrombocytopenia with chemotherapy plus nintedanib.”
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
“Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer. TACTI-004 registrational trial will enroll ~750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy.”
Doctor with cancer gets unprecedented liver, double-lung transplant from Northwestern Medicine
“t’s a medical story that’s off the charts. Northwestern surgeons have successfully performed a combined lung-liver transplant on a patient who had advanced lung cancer. And the patient is a doctor himself.”
Strategy may reduce tobacco treatment disparities among people with cancer
“A universal screening and opt-out referral strategy may reduce disparities in tobacco treatment access and increase use of smoking cessation services by people with cancer, according to results of a qualitative improvement study.”
RPL13A and GNL3 May Help Assess Immunotherapy Resistance for NSCLC
“Ribosomal RNA genes, ribosomal protein L13a (RPL13A) and G protein nucleolar (GNL3), may be used to help assess immunotherapy resistance for patients with non-small cell lung cancer (NSCLC), according to a study published in the Journal for Immunotherapy of Cancer.”
Automated PD-L1 status prediction in lung cancer with multi-modal PET/CT fusion
“Programmed death-ligand 1 (PD-L1) expressions play a crucial role in guiding therapeutic interventions such as the use of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in lung cancer. Conventional determination of PD-L1 status includes careful surgical or biopsied tumor specimens. These specimens are gathered through invasive procedures, representing a risk of difficulties and potential challenges in getting reliable and representative tissue samples.”
Beyond Docetaxel: Adagrasib Shows Promise in KRAS G12C-Mutant NSCLC
“Adagrasib (Krazati) showed deep, durable responses in patients with previously treated KRAS G12C-mutated non–small cell lung cancer (NSCLC) in the phase 1/2 KRYSTAL-1 trial (NCT03785249). The phase 3 KRYSTAL-12 study (NCT0468513) sought to build on these findings and compared adagrasib with docetaxel in this intent-to-treat population.”
Research points the way toward an exhaled-breath test for lung cancer
“The foundational science to develop an exhaled-breath test for detection of lung diseases, including lung cancer, is underway, according to new research published by a laboratory at the Hackensack Meridian Center for Discovery and Innovation (CDI).”
Diabetes Drug may make lung cancer treatment more effective
“A medication used to treat diabetic neuropathy may make chemotherapy treatments more effective for patients with lung cancer, according to a new study.”
FDA Grants Fast Track Designation to Abdera Therapeutics’ Treatment for Extensive-Stage Small Cell Lung Cancer
“The FDA has granted Fast Track Designation to Abdera Therapeutics’ ABD-147, a next-generation precision radiopharmaceutical therapy designed for patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed following platinum-based chemotherapy. According to the company, ABD-147 implements advanced antibody engineering to deliver Actinium-225 to solid tumors expressing DLL3, which is a protein commonly found on neuroendocrine tumors but rarely expressed on the surface of normal cells or tissues.”
NSCLC Biomarker Testing: Some Pulmonologists Defer Testing to Oncologists
“NSCLC biomarker testing was ordered by 62% of pulmonologist-survey respondents for at least some of their patients and by 36% for most or all patients.”
Immunotherapy Has Improved Survival in Metastatic NSCLC
“Patients treated in the immunotherapy era had significantly better overall survival and cancer-specific survival than patients treated in the pre-immunotherapy era.”
Closing the Gap: New Campaign Focuses on Increasing Biomarker Testing in High-Risk Communities
“CHICAGO, July 16, 2024 /PRNewswire/ — About every two and a half minutes, someone in the U.S. is diagnosed with lung cancer. Thankfully, access to early diagnosis, precision medicine and biomarker testing can save lives and may provide for a better quality of life for people living with lung cancer. Unfortunately, biomarker testing is often underutilized, especially in the Black community. To address this disparity and improve the lives of people impacted by lung cancer, today, the American Lung Association launched Biomarker, Education, Awareness and Testing (BEAT) Lung Cancer, a new initiative for biomarker education and awareness, with a focus on increasing biomarker testing rates in communities most impacted by lung cancer disparities.”
Video:
Radiation a Curative-Intent Option in NSCLC and Interstitial Lung Disease
“Stereotactic ablative radiotherapy (SABR) has been found to be a viable curative-intent treatment option among some patients with early-stage non-small cell lung cancer (NSCLC) and lung scarring known as interstitial lung disease, according to research.”
Approach to Treating Patients with NSCLC with Uncommon EGFR Mutations
